UNSPSC 51323201: Cerivastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C26H34FNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AM91H2KS67, chemically known as 6-heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (s-(r*,s*-(e)))- but generally known as cerivastatin, which bears US NIH Compound Identifier 446156. European Medicines Agency schedules Cerivastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07440MIG.

UNSPSC 51323201 Cerivastatin is a Commodity code representing a specific statin medication, though recent state and local procurement activity under this code involves broader pharmaceutical procurement spanning multiple medication classes and OTC products supplied to emergency medical services, health plans, and cooperative purchasing networks. State and local governments are buying advanced life support medications, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs through this taxonomy. Issuing bodies include municipal fire departments, state health and human services agencies, and regional cooperative purchasing alliances. The City of Tampa Fire Rescue and the Texas Health and Human Services Commission represent end-use demand, while MMCAP (Minnesota Multistate Cooperative Purchasing Alliance) coordinates purchasing across multiple state and local members. Vendors supplying under this code must meet cGMP certification, DSCSA compliance, and FDA regulatory requirements; maintain comprehensive insurance; provide Safety Data Sheets and accessibility documentation; and negotiate pricing through wholesaler networks, direct contracting with self-insured plans, or cooperative discount models.

Recent activity spans Florida, Minnesota (serving multiple states including Oregon), and Texas. The City of Tampa's sealed-bid solicitation (26P00188, due April 8, 2026, estimated value $40,000) seeks four specific advanced life support medications—Labetalol, Epinephrine, Adenosine, and Diltiazem—for Tampa Fire Rescue with nine-month minimum expiration dates and one-year initial contract terms renewable for two additional years plus optional 30-day extensions, with a 5 percent SLBE bid discount not to exceed $10,000. MMCAP's RFP (S1070000015802, due March 26, 2026) establishes multi-award generic pharmaceuticals and OTC contracts across participating state and local facilities, effective July 1, 2026, with two-year initial terms and evaluations weighted 75 percent to price competitiveness, while vendors must maintain relationships with three authorized wholesalers and comply with electronic data interchange and administrative fee requirements. Texas HHS's RFI (HHS0017013, April 3, 2026 response) seeks vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, signaling exploration of alternative procurement models ahead of future formal RFP release.